Aflibercept ophthalmic pharmaceutical composition
US10646546B2 · kind B2 · utility
1Cited by
8References
12Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Oct 13, 2017 |
| Grant date | May 12, 2020 |
| Priority date | — |
| Expiry date | Oct 13, 2037 |
Classification
- Technology area (CPC A)Human Necessities
- CPC primaryA61P27/02
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
Provided is an ophthalmic pharmaceutical composition having a certain pH, comprising aflibercept as an active ingredient and an acetate salt buffering agent, wherein the composition is free of an ionic tonicity agent, remarkably reduces the formation of dimeric and multimeric impurities, and maintains the biological activity in a high level for a long time, under the accelerated and stress conditions as well as under the cold storage condition.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.